High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 4, 2010, Pages 275-281

  Nguyen, T M H ^a   Le Gall, C ^b   Lachaux, A ^b   Boulieu, R ^a,c  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

5 aminosalicylic acid derivatives; Azathioprine; Inflammatory bowel disease; Pediatric; RBC thiopurine metabolites

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE; THIOGUANOSINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD CELL COUNT; CHILD; CONTROLLED STUDY; DRUG POTENTIATION; ENTERITIS; FEMALE; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; REMISSION; RISK FACTOR;

EID: 77950991811     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48275     Document Type: Article

References (36)

1. Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther. 2003; 17: 69-73.
2. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993; 34: 1081-1085.
3. Coulthard S, Hogarth L. The thiopurine: An update. Invest New Drugs. 2005; 23: 523-532.
4. De Boer NKH et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007; 102: 2747-2753.
5. Derijks LJJ et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: Implication for therapy. Ther Drug Monit. 2004; 26: 311-318. (Pubitemid 38703020)
6. Derijks LJJ, Gilissen LPL, Hooymans PM, Hommes DW. Thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 24: 715-729.
7. Dervieux T, Boulieu R. Identification of 6-methyl-mercaptopurine derivative formed during acid hydrolysis of thiopurine nucleotides in erythrocytes, using liquid chromatography-mass spectrometry, infrared spectroscopy, and nuclear magnetic resonance assay. Clinical Chemistry. 1998; 44: 2511-2515.
8. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clinical Chemistry. 1998; 44: 551-555. (Pubitemid 28141350)
9. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther. 2005; 16: 79-85.
10. Dubinsky MC, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000; 118: 705-713.
11. Dubinsky MC et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122: 904-915.
12. Duley JA, Florin THJ. Thiopurine therapies: Problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit. 2005; 27: 647-654.
13. El-Azhary RA. Azathioprine: current status and future considerations. International Journal of Dermatology. 2003; 42: 335-341. (Pubitemid 36681712)
14. Fargher EA et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007; 32: 187-195.
15. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30-year review. Gut. 2002; 50: 485-489. (Pubitemid 34638866)
16. Gardiner SJ, Begg EG. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006; 58: 521-590. (Pubitemid 44403684)
17. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics andmetabolitemonitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005; 20: 1149-1157. (Pubitemid 41602556)
18. Gilissen LPL et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2005; 22: 605-661.
19. Hande S et al. 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory Bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006; 12: 251-257. (Pubitemid 43754643)
20. Järnerot G. Medical therapy of active Crohn's disease. Clinical Gastroenterology. 1998; 12: 73-92. (Pubitemid 28327294)
21. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002; 51: 143-146. (Pubitemid 34791433)
22. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43: 329-339.
23. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 940-987. (Pubitemid 43374543)
24. Lowry PW et al. Leucopenia resulting froma drug interaction between azathioprine or 6-mercaptopurine andmesalamine, sulphasalazine, or balsalazide. Gut. 2001; 49: 656-664.
25. Nielsen OH, Vainer B, Rask-Madsen J. The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001; 15: 1699-1708. (Pubitemid 33001133)
26. Mantzaris GJ et al. A prospective randomized observer-blind 2 year trial of azathioprinemonotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid dependant ulcerative colitis. Am J Gastroenterol. 2004; 99: 1121-1128.
27. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995; 123: 132-142.
28. Rosen R, Integlia MJ, Bousvaros A. Severe pancytopenia from thiopurine methyltransferase deficiency: A preventable complication of 6-mercaptopurine therapy in children with Crohn's disease. J Pediatr Gastroenterol Nutr. 2002; 35: 695-699. (Pubitemid 35417746)
29. Sandborn WJ et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews CD000545 1998.
30. Sandborn WJ, Hanauer SB. Systematic review: The pharmacokinetics of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003; 17: 29-42.
31. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000; 118: 68-82.
32. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercapopurine and azathioprine. Br J Clin Pharmacol. 1995; 39: 456-459.
33. Telm A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease. Clin Pharmacokinet. 2007; 46: 187-208.
34. Timmer A, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews CD000478 2007. (Pubitemid 47055637)
35. Travis SPL et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 (Suppl 1): 16-35.
36. Xin H, Fischier C, Schwab M, Klotz U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 21: 1105-1109 (Pubitemid 40646536)